News

Tigermed-Jyton supports China NMPA Approval of Retoxin® ——The World’s First Clinical Trial on Therapeutic Indication of Recombinant Botulinum Toxin Type A

Tigermed-Jyton supports China NMPA Approval of Respacio® ——The First lsolation Hydrogel for Cervical Cancer Radiotherapy In The Word

Tigermed-Jyton Supports the Multi-center Clinical Registration Study of the First Modular General Microsurgical Robot in China

Womed Leaf, US’s First-in-Class degradable film for treating intrauterine adhesion received approval by FDA, Tigermed-Jyton CRO service made great contribution

Tigermed Supports FDA Clearance of Fasikl’s Felix™ NeuroAI™ Wristband —the First AI-Powered Wearable Approved for Essential Tremor

Tigermed-Jyton Supports the Approval of the First Hyaluronic Acid Sodium Composite Solution in the China Market.

Visit Tigermed-Jyton Stand at the MEDICA German Medical Exhibition 2024

Tigermed-Jyton Supports the Approval of Brattea's Innovative RDN System

Tigermed-Jyton Supports the Approval of the World’s First Renal Nerve Mapping Renal Artery Radiofrequency Ablation Product (msRDN)

Tigermed-Jyton Announces Acquisition of NAMSA China and Global Strategic Partnership with NAMSA

BEIJING, CHINA and TOLEDO, US –February 29, 2024—Tigermed-Jyton, a leading medical device CRO in China, and NAMSA, a global leader MedTech Contract Research Organization (CRO) offering global end-to-end development services, today announced Tigermed-Jyton’s acquisition of NAMSA China, as well as the exclusive China region partnership and global collaboration between Tigermed-Jyton and NAMSA.